Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor

Journal of Urology

Volumn 158, Issue 3, 1997, Pages 740-745

  Figlin, Robert A ^a   Pierce, William C ^b   Kaboo, Randir ^b   Tso, Cho Lea ^b   Moldawer, Nancy ^b   Gitlitz, Barbara ^b   Dekernion, Jean ^b   Belldegrun, Arie ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Carcinoma; Interleukin 2; Nephrectomy; Renal cell

Indexed keywords

OKT 8; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0030818791     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64304-0     Document Type: Article

References (26)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer Statistics, 1996. CA Cancer J. Clin., 46: 5, 1996.
2. SEER Cancer Statistics Review, 1973-1990. National Institutes of Health Publication No. 93-2789. Bethesda, Maryland: Public Health Service, United States Department of Health and Human Services, 1990.
3. McNichols, D. W., Segura, J. W. and DeWeerd, J. H.: Renal cell carcinoma: long-term survival and late recurrence. J. Urol., 126: 17, 1981.
4. Golimbu, M., Joshi, P., Sperber, A., Tessler, A., Al-Askari, A. and Morales, P.: Renal cell carcinoma: survival and prognostic factors. Urology, 27: 291, 1986.
5. Bassil, B. A., Dosoretz, D. E. and Prout, G. R., Jr.: Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J. Urol., 134: 450, 1985.
6. Taneja, S. S., Pierce, W., Figlin, R. A. and Belldegrun, A.: Management of disseminated kidney cancer. Urol. Clin. N. Amer., 21: 626, 1994.
7. deKernion, J. B., Ramming, K. P. and Smith, R. B.: The natural history of metastatic renal cell carcinoma: a computer analysis. J. Urol., 120: 148, 1978.
8. Choudhury, M., Efros, M. and Mittelman, A.: Interferons and interleukins in metastatic renal cell carcinoma. Urology, suppl., 41: 67, 1993.
9. Thrasher, J. B. and Paulson, D. F.: Prognostic factors in renal cancer. Urol. Clin. N. Amer., 20: 247, 1993.
10. Elson, P. J., Witte, R. S. and Trump, D. E.: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res., 48: 7310, 1988.
11. Montie, J. E., Stewart, B. H., Straffon, R. A., Banowsky, L. H. W., Hewitt, C. B. and Montague, D. K.: The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol., 117: 272, 1977.
12. Lotze, M. T., Chang, A. E., Seipp, C. A., Simpson, C., Vetto, J. T. and Rosenberg, S. A.: High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. J.A.M.A., 256: 3117, 1986.
13. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R. and Louie, A. C.: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol., 13: 688, 1995.
14. Yang, J. C., Topalian, S. L., Parkinson, D., Schwartzentruber, D. J., Weber, J. S., Ettinghausen, S. E., White, D. E., Steinberg, S. M., Cole, D. J. and Kim, H. I.: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol., 12: 1572, 1994.
15. Belldegrun, A., Muul, L. M. and Rosenberg, S. A.: Interleukin-2 expanded lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res., 48: 206, 1988.
16. Spiess, P. J., Yang, J. C. and Rosenberg, S. A.: In vivo antitumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2. J. Nat. Cancer Inst., 79: 1067, 1987.
17. Rosenberg, S. A., Schwartz, S. and Spiess, P. J.: Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alpha-interferon, and tumor-infiltrating lymphocytes. J. Nat. Cancer Inst., 80: 1393, 1988.
18. Seliger, B., Hohne, A., Knuth, A., Bernhard, H., Meyer, T., Tampe, R., Momburg, F. and Huber, C.: Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res., 56: 1756, 1996.
19. Morecki, S., Topalian, S. L., Myers, W. W., Okrongly, D., Okarma, T. B. and Rosenberg, S. A.: Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks. J. Biol. Response Modifiers, 9: 463, 1990.
20. Letessier, E. M., Heo, D. S., Okarma, T. B., Johnson, J. T., Herberman, R. B. and Whiteside, T. L.: Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer. Cancer Res., 51: 3891, 1991.
21. Walther, M. M., Alexander, R. B., Weiss, G. H., Venzon, D., Berman, A., Pass, H. I., Linehan, W. M. and Rosenberg, S. A.: Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 42: 250, 1993.
22. Topalian, S. L., Solomon, D., Avis, F. P., Chang, A. E., Freerkson, D. L., Linehan, W. M., Lotze, M. T., Robertsen, C. N., Seipp, C. A. and Simon, P.: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol 6: 839 1988.
23. Kradin, R. L., Kurnick, J. T., Lazarus, D. S., Preffer, F. I., Dubinett, S. M., Pinto, O. E., Gifford, J., Davidson, E., Grove, B. and Callahan, R. J.: Tumuor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet, 1: 577 1989.
24. Bukowski, R. M., Sharfman, W., Murthy, S., Rayman, P., Tubbs, R., Alexander, J., Budd, J. T., Sergi, J. S., Bauer, L. and Gibson, V.: Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res., 51: 4199, 1991.
25. Figlin, R. A., Belldegrun, A., Moldawer, N., Zeffren, J. and deKernion, J. B.: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J. Clin. Oncol., 10: 414, 1992.
26. Belldegrun, A., Tso, C. L., Kaboo, R., Pang, S., Pierce, W., deKernion, J. B. and Figlin, R.: Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2 based therapy. J. Immunother., 19: 149 1996.